Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Respir Rev. 2014 Sep;23(133):333-44. doi: 10.1183/09059180.00004014.

Addressing unmet needs in the treatment of COPD.

Author information

  • 1Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. francesco.patalano@novartis.com.
  • 2Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Abstract

The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised.

©ERS 2014.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk